Literature DB >> 2546244

Mucocutaneous dissemination of acyclovir-resistant herpes simplex virus in a patient with AIDS.

G L Marks1, P E Nolan, K S Erlich, M N Ellis.   

Abstract

Infections caused by herpes simplex virus (HSV) are a significant source of morbidity in immunocompromised patients. Acyclovir is often used prophylactically and therapeutically in patients with human immunodeficiency virus infection. The emergence of acyclovir-resistant strains of HSV capable of causing disease has been recognized. We report a case in which a thymidine kinase-deficient mutant of HSV caused extensive disease in a patient with AIDS. This case emphasizes that virus recovered from nonhealing lesions should be submitted for further study, which may advance our understanding of the interaction between host defense and drug-resistant strains.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2546244     DOI： 10.1093/clinids/11.3.474

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN： 0162-0886


  10 in total

Review 1.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

3.  In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.

Authors:  E L Hill; G A Hunter; M N Ellis
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 4.  Herpes latency, meningitis, radiculomyelopathy and disseminated infection.

Authors:  J J Sasadeusz; S L Sacks
Journal:  Genitourin Med       Date:  1994-12

Review 5.  "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs.

Authors:  A K Field; K K Biron
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

6.  Lack of association of herpes simplex virus type 2 seropositivity with the progression of HIV infection in the HERS cohort.

Authors:  Brooke E Hoots; Michael G Hudgens; Stephen R Cole; Caroline C King; Robert S Klein; Kenneth H Mayer; Anne M Rompalo; Jack D Sobel; Denise J Jamieson; Jennifer S Smith
Journal:  Am J Epidemiol       Date:  2011-03-03       Impact factor: 4.897

7.  Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.

Authors:  J Piret; A Désormeaux; H Cormier; J Lamontagne; P Gourde; J Juhász; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 8.  Clinical and therapeutic issues for herpes simplex virus-2 and HIV co-infection.

Authors:  Jairam R Lingappa; Connie Celum
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Acyclovir diphosphate dimyristoylglycerol: a phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus.

Authors:  K Y Hostetler; S Parker; C N Sridhar; M J Martin; J L Li; L M Stuhmiller; G M van Wijk; H van den Bosch; M F Gardner; K A Aldern
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

10.  Study of Antiherpetic Efficiency of Phosphite of Acycloguanosine Ableto Over come the Barrier of Resistance to Acyclovir.

Authors:  V L Andronova; M V Jasko; M K Kukhanova; G A Galegov; Yr S Skoblov; S N Kochetkov
Journal:  Acta Naturae       Date:  2016 Jan-Mar       Impact factor: 1.845
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.